Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN022 in Subjects With Advanced Malignant Solid Tumors
Conditions
Interventions
JSKN022
Locations
1
China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Start Date
October 23, 2025
Primary Completion Date
August 31, 2027
Completion Date
December 31, 2027
Last Updated
December 23, 2025
NCT06658951
NCT06717750
NCT06912152
NCT07480733
NCT07363369
NCT06231550
Lead Sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions